HomePipelinePNB-091Cocaine Addiction
PNB-091
Cocaine Addiction
PNB-091 for Cocaine Addiction
- Molecule
- PNB-091
- Development status
- IND ready
- Therapeutic area
- CNS & addiction
- Biological action
- Pan-CCK blocker
- Therapeutic target
- Pan- Cholecystokinin Receptors, dopamine modulation
- Therapeutic indication
- Cocaine antagonist
Stage of development
-
PNB-091
Cocaine AddictionPan-CCK blocker
- Molecule
- PNB-091
- Indication
- Cocaine Addiction
- Biological action
- Pan-CCK blocker
- Status
- IND ready
- Background about target:
CCK neurons and dopamine receptors are collocated and here apomorphine mediated action were antagonized without sedation. Most interestingly are other neuropeptide interactions which are released in response to sex, gambling and illicit drug use. Here the targeted approach of PNB001 is modulating this most relevant neuropeptide action in addition to the known DA pathways.
- Preclinical studies:
PNB-091 is a non-selective mixed CCK antagonist, inhibiting the effects of gastrin and cholecystokinin. Efficacy testing was initially performed in anxiety and depression tests as x-maze, B/W box and swim test. Locomotion studies were performed in collaboration with NIDA (National Institute of Drug Addiction) and followed by substitution and antagonistic cocaine models. The use in preventing addiction was shown in more sophisticated assays as the frequency rate intracranial self-stimulation in rats. These assays required surgery and extensive training.
- Preclinical development studies:
DMPK studies with PNB-091 indicated that the NCE was stable in rat, dog, and human liver microsomes. One site of metabolism is protected by a fluorine atom and the benzyl group is best in SAR for affinity and selectivity. Most importantly, with a low polar surface area a high membrane penetration was achieved. Studies, including CaCo2 permeability and plasma protein binding, demonstrated favorable druggable properties of PNB-091.
- Synthetic chemistry:
PNB-091 synthetic scheme has only two steps and involve highly economical raw materials. PNB-091can be synthesized on a large scale with high purity exceeding 99.7%.
- Ongoing studies:
Preclinical toxicology and safety pharmacology regulatory studies in accordance to ICH guidelines to be launched.
- Intellectual property:
PNB-091 and structurally related molecules are well protected with patents filed in the US, Europe, and rest of the World. Examination by the PTO office in Washington DC did not find any infringement issues with this series of molecules. USPTO has issued the patent on December 28, 2014.
About PNB-091
IND ready
Developed in collaboration with the US National Institute on Drug Abuse (NIDA) for drug abuse and addiction, with anxiolytic and antidepressant properties.
PNB-091 full profileInterested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
